What question did this study set out to answer?

To determine whether K-ras gene mutation status influences survival benefit from cetuximab in patients with advanced colorectal cancer.

October 22, 2008New England Journal of Medicine

K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer

View Full Paper

Ask AI

Bookmark

Authors

CKChristos S. KarapetisFlinders University SKShirin Khambata‐FordDaiichi Sankyo (United States)DJDerek J. JonkerUniversity of Ottawa

Discussion

Member takes

Implication

Randomized trial demonstrates cetuximab efficacy strictly in wild-type K-ras advanced colorectal cancer, indicating mutation status dictates treatment response.

Key Points

To determine whether K-ras gene mutation status influences survival benefit from cetuximab in patients with advanced colorectal cancer.
Randomized trial (ClinicalTrials.gov number, NCT00079066) assessing cetuximab versus best supportive care alone in advanced colorectal cancer.
Tumor samples evaluated for wild-type versus mutated K-ras status to analyze treatment efficacy by mutation subgroup.
Patients with wild-type K-ras tumors derived a clinical benefit from cetuximab therapy, whereas patients with mutated K-ras tumors experienced no benefit.
K-ras mutation status did not affect survival among patients who received best supportive care alone.

Cite This Study

Karapetis et al. (2008) studied this question.

synapsesocial.com/papers/69d78ccc6cc86f5f11b8a385 https://doi.org/10.1056/nejmoa0804385

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial demonstrates cetuximab efficacy strictly in wild-type K-ras advanced colorectal cancer, indicating mutation status dictates treatment response.

K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider